Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM2: Fedratinib vs BAT in Myelofibrosis
NCT03952039Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of fedratinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Spleen Volume Response Rate (>= 35% reduction) at Cycle 6. Started Sep 2019; status: completed.
02
Drugs
fedratinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT03952039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952039.